SCHEMBL20600646

SCHEMBL20600646

Nc1cc(-c2c(-c3cccc(F)c3)nc(N)c3nccn23)cc2cccnc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA1 P42261 3/20 0.43
PDE4A P27815 2/20 0.39
PDE4B Q07343 2/20 0.39
PDE4C Q08493 2/20 0.39
PDE4D Q08499 2/20 0.39
ADORA2A P29274 3/20 0.38
ADORA1 P30542 2/20 0.37
ADORA3 P0DMS8 1/20 0.37
CSNK1E P49674 3/20 0.37
CCNA2 P20248 2/20 0.37
CDK2 P24941 2/20 0.37
CDK5 Q00535 2/20 0.37
CDK5R1 Q15078 2/20 0.37
CCNT1 O60563 1/20 0.37
CDK9 P50750 1/20 0.37
HASPIN Q8TF76 1/20 0.37
DPP4 P27487 1/20 0.36
AKT1 P31749 1/20 0.36
AKT2 P31751 1/20 0.36
BCHE P06276 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20600432 0.92 ADORA2A (0.46) GRIA1PDE4APDE4BPDE4CPDE4D
SCHEMBL20600466 0.90 ADORA2A (0.43) GRIA1PDE4APDE4BPDE4CPDE4D
SCHEMBL20600564 0.90 ADORA2A (0.44) GRIA1PDE4APDE4BPDE4CPDE4D
SCHEMBL20600645 0.88 GRIA1 (0.41) GRIA1PDE4APDE4BPDE4CPDE4D
SCHEMBL20600575 0.87 GRIA1 (0.40) GRIA1PDE4APDE4BPDE4CPDE4D
SCHEMBL20600433 0.87 TNK2 (0.42) GRIA1PDE4APDE4BPDE4CPDE4D
SCHEMBL20600608 0.87 GRIA1 (0.40) GRIA1PDE4APDE4BPDE4CPDE4D
SCHEMBL20600451 0.87 MAP4K4 (0.44) GRIA1PDE4APDE4BPDE4CPDE4D
SCHEMBL20600582 0.86 GRIA1 (0.43) GRIA1PDE4APDE4BPDE4CPDE4D
SCHEMBL20600534 0.85 ADORA2A (0.48) PDE4APDE4BPDE4CPDE4DADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-11-26 US claimed
EP-3645536-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-05-06 EP claimed
WO-2019002606-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR SELVITA S.A. (PL) 2019-01-03 WO claimed
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-11-26 US disclosed
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-11-26 US disclosed
EP-3645536-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-05-06 EP disclosed
WO-2019002606-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR SELVITA S.A. (PL) 2019-01-03 WO disclosed
WO-2019002606-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR SELVITA S.A. (PL) 2019-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR ADORA2A, ADORA1, ADORA3 GRIA1 475/4885PDE4A 110/4885PDE4B 183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.